1. Home
  2. MDA vs ACAD Comparison

MDA vs ACAD Comparison

Compare MDA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MDA

MDA Space Ltd. Common Shares

N/A

Current Price

$32.24

Market Cap

4.2B

ML Signal

N/A

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.89

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDA
ACAD
Founded
1969
1993
Country
Canada
United States
Employees
4000
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
3.8B
IPO Year
2026
2000

Fundamental Metrics

Financial Performance
Metric
MDA
ACAD
Price
$32.24
$21.89
Analyst Decision
Strong Buy
Buy
Analyst Count
2
22
Target Price
$37.50
$30.55
AVG Volume (30 Days)
689.6K
1.4M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
N/A
2.30
Revenue
N/A
$726,437,000.00
Revenue This Year
$12.11
$18.80
Revenue Next Year
$11.03
$11.70
P/E Ratio
N/A
$9.58
Revenue Growth
N/A
40.45
52 Week Low
$23.23
$14.18
52 Week High
$37.45
$28.35

Technical Indicators

Market Signals
Indicator
MDA
ACAD
Relative Strength Index (RSI) 49.87 48.87
Support Level $23.23 $20.81
Resistance Level $33.75 $22.03
Average True Range (ATR) 1.75 0.61
MACD 0.23 0.06
Stochastic Oscillator 44.63 48.95

Price Performance

Historical Comparison
MDA
ACAD

About MDA MDA Space Ltd. Common Shares

MDA Space Ltd is a developer and manufacturer of technology and services to the space industry. It is an international space mission partner and robotics, satellite systems, and geo-intelligence pioneer. It is engaged in communications satellites, Earth and space observation, space exploration, and infrastructure. The Company collaborates and partners with governments and space agencies, commercial space companies, and defence and aerospace prime contractors in the space industry. Geographically, it generates the majority of its revenue from Canada.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: